This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Isosorbide dinitrate and hydralazine (extended release)
Description: BiDil is a combination of two drugs, isosorbide dinitrate and hydralazine. Isosorbide dinitrate is a nitric oxide donor while hydralazine is an antioxidant and vasodilator agent (alters calcium metabolism in smooth muscles). They work in combination to dilate blood vessels.
BiDil XR is an extended-release formulation of BiDil.
Deal Structure: In February 2007, NitroMed entered into a License Agreement with Elan. Pursuant to the Agreement, Elan granted to NitroMed an exclusive worldwide license so that NitroMed may import, use, offer for sale and sell the oral capsule formulation incorporating specified technology referred to in the Agreement as the Elan Technology and containing, as its sole active combination of ingredients, the combination of the active drug substances isosorbide dinitrate and hydralazine hydrochloride.
In consideration for the grant of the License, NitroMed has agreed to pay Elan royalties that are calculated by reference to annual net sales parameters set forth in the Agreement. In addition, NitroMed has agreed to pay Elan specified amounts upon the achievement of specified development and commercialization milestone events set forth in the Agreement. Pursuant to the terms of the Agreement, Elan shall be and shall remain the owner of the Elan Intellectual Property.
In October 2008, NitroMed...See full deal structure in Biomedtracker
Partners: Perrigo Company PLC
BiDil XR News
Pink Sheet NitroMed Looks To 2010 NDA For BiDil XR
Additional information available to subscribers only: